Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Détails

ID Serval
serval:BIB_7F8DDEE8DA1E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Périodique
Nature reviews. Clinical oncology
Auteur(s)
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F., Thompson J.A., Obeid M.
ISSN
1759-4782 (Electronic)
ISSN-L
1759-4774
Statut éditorial
Publié
Date de publication
09/2019
Peer-reviewed
Oui
Volume
16
Numéro
9
Pages
563-580
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for these agents continue to expand across malignancies and disease settings, thus reshaping many of the previous standard-of-care approaches and bringing new hope to patients. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), which are often distinctly different from the classical chemotherapy-related toxicities. Owing to the growing use of ICIs in oncology, clinicians will increasingly be confronted with common but also rare irAEs; hence, awareness needs to be raised regarding the clinical presentation, diagnosis and management of these toxicities. In this Review, we provide an overview of the various types of irAEs that have emerged to date. We discuss the epidemiology of these events and their kinetics, risk factors, subtypes and pathophysiology, as well as new insights regarding screening and surveillance strategies. We also highlight the most important aspects of the management of irAEs.
Mots-clé
Antineoplastic Agents, Immunological/adverse effects, Drug-Related Side Effects and Adverse Reactions/diagnosis, Drug-Related Side Effects and Adverse Reactions/epidemiology, Drug-Related Side Effects and Adverse Reactions/therapy, Humans, Immunologic Factors/adverse effects, Immunotherapy/adverse effects, Immunotherapy/methods, Neoplasms/drug therapy
Pubmed
Web of science
Création de la notice
21/05/2019 7:28
Dernière modification de la notice
12/02/2020 6:19
Données d'usage